Merck KGaA is in "advanced discussions" to divest its biosimilars business unit – which includes a copycat version of AbbVie Inc.'s best-selling immunology drug Humira (adalimumab) – as part of an ongoing restructuring process, the company announced during its March 9 annual results presentation. The divesture of this unit would also cut down on R&D costs to the company, which said it spent around €130m on biosimilars in 2016; mostly on R&D, as well as on manufacturing work and preparation for commercialization.
At present, Merck has no revenue streams from its biosimilar drugs but its biosimilar adalimumab product, MSB11022, is in Phase...








